康弘药业：子公司康柏西普眼用注射液获临床试验补充申请批准

Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Kanghong Biotech, has received approval from the National Medical Products Administration for clinical trials of its innovative drug, Conbercept, which aims to enhance patient compliance and reduce medical burdens [1] Group 1: Drug Approval and Development - Kanghong Biotech's Conbercept is classified as a Class 1 biological innovative drug with complete independent intellectual property rights [1] - The approval includes the acceptance numbers CXSB2500193 and CXSB2500194, allowing the company to conduct clinical trials [1] - This trial represents an exploration of high-dose applications in clinical settings [1] Group 2: Market Implications - The drug has the potential to improve patient medication adherence, which could lead to a reduction in overall healthcare costs [1] - The development and approval processes for pharmaceuticals carry inherent uncertainties, which may impact investor sentiment [1]